Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NHS England Backs Biosimilar-To-Biosimilar Switching As It Counts Adalimumab Savings

Executive Summary

Switching between biosimilars does not appear to raise safety concerns, according to NHS England, which is anticipating more than £300m in annual savings from biosimilar competition on adalimumab.

You may also be interested in...



BGMA Urges UK To Hold Firm On Trade Deals

Responding to UK government statements on the country’s future approach to trade deals with non-EU nations, the BGMA has insisted that there must be no changes to patent and exclusivity provisions that would block market entry for generic and biosimilar medicines.

US Pharma Firms Not In Post-Brexit Trade Talks

A UK TV program revealed secret meetings between drug makers and British civil servants but for its part, the American Pharmaceutical Group says it has had no discussions

Nine Factors Can Drive Hospital-Sector Savings

A KPMG report commissioned by Medicines for Europe finds that nine ‘key ingredients’ could maximize savings for generic and biosimilar medicines in European hospitals.

Related Content

Topics

UsernamePublicRestriction

Register

LL1134531

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel